ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

NBIX Neurocrine Biosciences Inc

144.00
0.81 (0.57%)
Pre Market
Last Updated: 12:12:05
Delayed by 15 minutes
Share Name Share Symbol Market Type
Neurocrine Biosciences Inc NASDAQ:NBIX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.81 0.57% 144.00 143.50 150.00 265 12:12:05

Neurocrine Biosciences to Present at Goldman Sachs 40th Annual Global Healthcare Conference

04/06/2019 9:01pm

PR Newswire (US)


Neurocrine Biosciences (NASDAQ:NBIX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Neurocrine Biosciences Charts.

SAN DIEGO, June 4, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Goldman Sachs 40th Annual Global Healthcare Conference at 10:00 a.m. PT (1:00 p.m. ET) on Tuesday, June 11, 2019, in Rancho Palos Verdes, Calif. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, of Neurocrine Biosciences will present at the conference.

(PRNewsfoto/Neurocrine Biosciences, Inc.)

The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences (Nasdaq: NBIX) is a neuroscience-focused, biopharmaceutical company with more than 25 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia and endometriosis* and clinical development programs in multiple therapeutic areas including Parkinson's disease, congenital adrenal hyperplasia and uterine fibroids*. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-goldman-sachs-40th-annual-global-healthcare-conference-300861785.html

SOURCE Neurocrine Biosciences, Inc.

Copyright 2019 PR Newswire

1 Year Neurocrine Biosciences Chart

1 Year Neurocrine Biosciences Chart

1 Month Neurocrine Biosciences Chart

1 Month Neurocrine Biosciences Chart

Your Recent History

Delayed Upgrade Clock